Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VSL#3 + inulin
- Development stage
- Unknown
- Lead developer
- VSL Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
VSL#3 + inulin is a synbiotic combination consisting of the high-potency probiotic formulation VSL#3 and the prebiotic fiber inulin. VSL#3 is a proprietary blend of eight live bacterial strains, including species of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus*. Inulin is a fructan-type polysaccharide that serves as a fermentable substrate to promote the growth of beneficial gut microbiota. This combination was evaluated in a Phase 2 clinical trial led by Radboud University Medical Center to determine its efficacy in preventing adenoma development in the ileal pouch of patients with familial adenomatous polyposis (FAP) who have undergone ileal pouch-anal anastomosis (IPAA). The treatment aims to modulate the luminal environment, enhance detoxification capacity, and reduce mucosal cell proliferation, potentially interrupting the adenoma-carcinoma sequence in the pouch.
- Brand names
- VSL#3
- Other names
- VSL#3/inulinVSL#3 and inulin
Beyond the preview
Go deeper on VSL#3 + inulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VSL#3 + inulin.